Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
Publication
, Conference
Wainberg, ZA; Boccia, RV; Strickler, JH; Moehler, MH; Sirard, CA; Walsh, EK; Parker, EC; Lee, K-W
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Start / End Page
TPS275 / TPS275
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wainberg, Z. A., Boccia, R. V., Strickler, J. H., Moehler, M. H., Sirard, C. A., Walsh, E. K., … Lee, K.-W. (2023). Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. TPS275–TPS275).
Wainberg, Zev A., Ralph V. Boccia, John H. Strickler, Markus H. Moehler, Cynthia A. Sirard, Erin K. Walsh, Elizabeth C. Parker, and Keun-Wook Lee. “Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).” In JOURNAL OF CLINICAL ONCOLOGY, 41:TPS275–TPS275, 2023.
Wainberg ZA, Boccia RV, Strickler JH, Moehler MH, Sirard CA, Walsh EK, et al. Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe). In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS275–TPS275.
Wainberg, Zev A., et al. “Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. TPS275–TPS275.
Wainberg ZA, Boccia RV, Strickler JH, Moehler MH, Sirard CA, Walsh EK, Parker EC, Lee K-W. Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe). JOURNAL OF CLINICAL ONCOLOGY. 2023. p. TPS275–TPS275.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Start / End Page
TPS275 / TPS275
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences